Two Data Analyses From Clinical Trials Show Epcoritamab Induces Durable Complete Reponses
January 2, 2025
AbbVie announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell